A043710 Stock Overview
Seouleaguer Co., Ltd., a medical beauty care platform company, provides hospital management support services in South Korea.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩1,520.00|
|52 Week High||₩2,045.00|
|52 Week Low||₩894.00|
|1 Month Change||3.05%|
|3 Month Change||55.26%|
|1 Year Change||-1.93%|
|3 Year Change||-39.68%|
|5 Year Change||-63.42%|
|Change since IPO||-94.57%|
Recent News & Updates
Is Seouleaguer (KOSDAQ:043710) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Here's Why Seouleaguer (KOSDAQ:043710) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|A043710||KR Healthcare||KR Market|
Return vs Industry: A043710 exceeded the KR Healthcare industry which returned -43.5% over the past year.
Return vs Market: A043710 exceeded the KR Market which returned -15.2% over the past year.
|A043710 Average Weekly Movement||17.3%|
|Healthcare Industry Average Movement||5.9%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.3%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A043710 is more volatile than 90% of KR stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: A043710's weekly volatility has increased from 11% to 17% over the past year.
About the Company
Seouleaguer Co., Ltd., a medical beauty care platform company, provides hospital management support services in South Korea. The company was formerly known as Rocketmobile Co., Ltd. and changed its name to Seouleaguer Co., Ltd.
Seouleaguer Fundamentals Summary
|A043710 fundamental statistics|
Is A043710 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A043710 income statement (TTM)|
|Cost of Revenue||₩14.83b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-30.79|
|Net Profit Margin||-8.11%|
How did A043710 perform over the long term?See historical performance and comparison
Is Seouleaguer undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A043710 (₩1520) is trading below our estimate of fair value (₩36303.93)
Significantly Below Fair Value: A043710 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A043710 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.
PE vs Market: A043710 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A043710's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A043710 is overvalued based on its PB Ratio (2.3x) compared to the KR Healthcare industry average (2.2x).
How is Seouleaguer forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Seouleaguer has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Seouleaguer performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A043710 is currently unprofitable.
Growing Profit Margin: A043710 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A043710 is unprofitable, and losses have increased over the past 5 years at a rate of 50% per year.
Accelerating Growth: Unable to compare A043710's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A043710 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (34.8%).
Return on Equity
High ROE: A043710 has a negative Return on Equity (-10.95%), as it is currently unprofitable.
How is Seouleaguer's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A043710's short term assets (₩20.5B) exceed its short term liabilities (₩8.0B).
Long Term Liabilities: A043710's short term assets (₩20.5B) exceed its long term liabilities (₩4.6B).
Debt to Equity History and Analysis
Debt Level: A043710 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A043710's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A043710 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A043710 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 7.1% per year.
What is Seouleaguer current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A043710's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A043710's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A043710's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A043710's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A043710 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Paek-Chol Kim (56 yo)
Paek-Chol Kim serves as Chief Executive Officer of Playtech Co., Ltd. Paek-Chol Kim was employed by Allianz Life Insurance Co., Ltd. Paek-Chol Kim completed Graduate School of Hanyang University.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.4%.
Seouleaguer Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Seouleaguer Co., Ltd.
- Ticker: A043710
- Exchange: KOSDAQ
- Founded: 1991
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: ₩59.530b
- Shares outstanding: 39.16m
- Website: https://www.seouleaguer.net
Number of Employees
- Seouleaguer Co., Ltd.
- 10, Nonhyeon-ro 163-gil
- 4th Floor
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.